SEC Form 4 · accession 0001712369-26-000008
Vaxcyte, Inc. · PCVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Moncef Slaoui
Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 23, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001649094
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $52.11 | Jun 22, 2026 | A | 26,061 | A | — | Jun 22, 2036 | Common Stock | 26,061 | 26,061 | D |
Explanation of responses
- F1Option shall vest over 36 months, 1/3 of which will vest on June 17, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.